Our Products
Loans
Cards
Insurance
Investment
Stock Market
Electronics Mall
CIBIL Score
Knowledge Centre
Academy 
Calculators
Our Services
My Account
Do not call
En
Fortis Healthcare Ltd. Share Price
Day's Range
Day's Range
Low
₹962.00
High
₹977.45
Price Summary
| Previous Close | ₹963.65 |
|---|---|
| Day's Range | ₹962.00 - ₹977.45 |
| Open | ₹975.50 |
| 52 Week Range | ₹667.20 - ₹1,104.30 |
| Volume | 7,36,724 |
| Market Cap | ₹0.07 |
Stocks Summary
| Trade Value ( ₹ in Lacs) | 7,133.13 |
|---|---|
| Market Cap (₹ in Mn) | 0.07 |
| Dividend Yield(%) | 0.10 |
| Price/Earning (TTM) | 75.76 |
| TTM EPS (₹) | 12.71 |
| P/E Ratio | 68.11 |
| Book Value(₹) | 7.56 |
| PAT Margin (%) | 10.40 |
| Face Value (₹) | 10.00 |
| ROCE(%) | 12.14 |
Financials
| Particulars | QTR FY (₹ in Millions) | Annual FY (₹ in Millions) |
|---|---|---|
| Net sales | 19282.6 | 68929.2 |
| Expenses | N/A | N/A |
| PBT | 2793.9 | 8579.7 |
| Operating profit | 0.0 | 0.0 |
| Net profit | 2543.0 | 6452.2 |
About Fortis Healthcare Ltd.
| Founded | 1996 |
|---|---|
| Managing Director | Ashutosh Raghuvanshi |
| NSE Symbol | FORTIS |
Peer Comparision
| Stocks Name | Market Cap (Cr)(₹) | Market Price (₹) | 52 Week Low-High (₹) |
|---|---|---|---|
| Sun Pharmaceutical Industries Ltd. | 4,51,074.97 | 1,879.90 | 1,548.00 - 1,548.00 |
| Divi's Laboratories Ltd. | 1,79,485.96 | 6,755.00 | 5,636.50 - 5,636.50 |
| Torrent Pharmaceuticals Ltd. | 1,49,124.14 | 4,386.00 | 3,102.00 - 3,102.00 |
| Apollo Hospitals Enterprise Ltd. | 1,16,201.01 | 8,077.00 | 6,696.50 - 6,696.50 |
| Cipla Ltd. | 1,15,640.69 | 1,431.55 | 1,165.70 - 1,165.70 |
| Dr. Reddy's Laboratories Ltd. | 1,11,589.46 | 1,336.95 | 1,148.40 - 1,148.40 |
| Lupin Ltd. | 1,03,966.32 | 2,273.90 | 1,836.80 - 1,836.80 |
| Mankind Pharma Ltd. | 1,03,368.09 | 2,507.00 | 1,909.70 - 1,909.70 |
| Max Healthcare Institute Ltd. | 1,02,190.60 | 1,050.05 | 903.00 - 903.00 |
| Zydus Lifesciences Ltd. | 1,01,755.41 | 1,011.25 | 835.50 - 835.50 |
No Records Found
Latest News
Fortis Healthcare informs about merger by absorption
In continuation of its earlier intimation dated January 16, 2026, and pursuant to Regulations 30 and 51 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015 (‘SEBI Listing Regulations’), Fortis Healthcare has informed that the Company has, on March 1, 2026 at 3:00 pm (IST), filed the certified copy of the order of the Hon’ble National Company Law Tribunal, Delhi Bench and Hon’ble National Company Law Tribunal, Chandigarh Bench with the Registrar of Companies, in accordance with the applicable provisions of the Companies Act, 2013, by submitting Form INC-28. Consequently, composite scheme of merger by absorption between Fortis Emergency Services (FESL), Fortis Cancer Care (FCCL), Fortis Health Management (East) (FHMEL) and Birdie & Birdie Realtors (B&B) with Fortis Hospitals (FHsL) (collectively wholly-owned subsidiaries) and their respective shareholders and creditors (‘Scheme of Arrangement’), has come into effect from the date of such filing, March 1, 2026.
The above information is a part of company’s filings submitted to BSE.
Fortis Healthcare informs about newspaper publication
Krishna Institute of Medical Sciences informs about investor presentation
Onesource Specialty Pharma informs about updates
Acutaas Chemicals informs about corporate presentation
No Records Found
Sign in to Unlock Offers!
We don't SPAM
Frequently Asked Questions
The current share price of Fortis Healthcare Ltd. is ₹963.65 as of 2026-05-15.
The market capitalisation of Fortis Healthcare Ltd. is ₹72,717.57 as of 2026-05-15.
The 1-year return of Fortis Healthcare Ltd. is 0.00% as of 2026-05-15.
The P/E ratio of Fortis Healthcare Ltd. is 68.11 as of 2026-05-17.
The 52-week high and low of Fortis Healthcare Ltd. are ₹1,104.30 and ₹667.20, respectively, as of 2026-05-15.
People Also Ask
Fortis Healthcare Ltd. operates a network of healthcare facilities across India and select international markets, with over 4,000 operational beds, as per company disclosures. Its services include multispecialty acute care, organ transplantation, cardiac care, oncology, neurosciences, orthopaedics, and fertility treatment. The company also operates diagnostic centres offering imaging and pathology services.
Fortis Healthcare has expanded its healthcare and diagnostics presence through acquisitions and strategic investments, as disclosed by the company. These include acquisitions in hospital operations and a minority stake in a diagnostics platform to support service integration. Fortis is majority-owned by IHH Healthcare Berhad, providing linkage to an international healthcare group, as per public disclosures.
Disclaimer
All content and research information displayed on the Site, are obtained from our partner Accord Fintech Private Limited. an authorized data feed vendor of BSE/NSE/MCX/NCDEX exchange. The data is provided on ‘As-Is’ basis and is not a live data feed but a feed with 15 minutes delay or more. Bajaj Markets does not warrant accuracy, completeness, timely availability of the information and data available on the Site. Past performance, when presented, is purely for reference purposes and is not a guarantee of similar future results.
The Services offered on the Site does not constitute investment advice in any manner whatsoever. You shall be solely responsible for any investment decisions made by placing reliance on the information provided on the Site.
Bajaj Markets partners with financial services entities for sourcing leads for services such as DEMAT accounts etc. In case you wish to avail the services, you shall be redirected to partners platform and shall be bound by the terms and conditions, privacy policy governing the said platform.
